Skip to content
Altius – Lifestyle
Author:
Praxis Precision Medicines, Inc.
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
March 30, 2026
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 4, 2026
←
Previous Page
1
2